Published in Hepatitis Weekly, December 9th, 2002
Researchers believe the pathogenesis of hepatocellular carcinoma, linked to viral hepatitis, cirrhosis, and exposure to liver toxins, is innately proangiogenic. Thus, scientists have begun to explore drugs that can block angiogenesis in hepatocellular carcinomas. There is at least one agent, a copper chelator known as trientine, that has demonstrated antiangiogenic effects in murine models of liver cancer.
According to Michihisa Moriguchi and coauthors at Kyoto Prefectural University of Medicine in Kyoto, Japan, trientine...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.